• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Antidepressant may reduce mental stress-induced myocardial ischemia (REMIT Trial)

byAndrew Bishara
May 22, 2013
in Cardiology, Psychiatry
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Rates of mental stress-induced myocardial ischemia (MSIMI) were significantly lower in patients taking escitalopram (Lexapro) vs. placebo at the end of 6 weeks.

2. Rates of exercise-induced myocardial ischemia (ESIMI) were not significantly reduced in patients taking escitalopram vs. placebo at the end of 6 weeks.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Mental stress-induced myocardial ischemia (MSIMI) in patients with pre-existing coronary heart disease (CHD) has been replicated frequently, and it is regarded to be just as, if not more, prognostic as exercise induced myocardial ischemia (ESIMI). However, no clearly beneficial therapeutic options have been demonstrated to deal with it. This study demonstrates that patients with stable CHD prone to MSIMI are 2.62 times less likely to experience MSIMI after 6 weeks when receiving escitalopram instead of placebo. The altered serotonin physiology, the greater improvement in hemodynamic responses and psychological functioning in the escitalopram group over the placebo group demonstrates an intertwining of cardiovascular reaction and psychological response. Nonetheless, there does not appear to be a singular, known  pathophysiologic mechanism to explain this. Additional clinical trials offering longer treatment period beyond 6 weeks, as well as a more detailed analysis of metabolic risk factors before and after treatment with an increased sample size may increase the generalizability of this study and elucidate the relationship between serotonergic function and cardiovascular health.

Click to read the study, published today in JAMA

Relevant Reading: Psychological Stress and Cardiovascular Disease

RELATED REPORTS

Febuxostat may be effective in preventing contrast-induced acute kidney injury

72- and 36-hour fever prevention post-cardiac arrest equivalent in preventing mortality

Synergistic interaction between risk burden and genetics for atrial fibrillation development

In-Depth [randomized, double-blind placebo-controlled trial]: This study randomized a total of 127 participants with clinically stable CHD (Coronary Heart Disease) who demonstrated MSIMI during baseline mental and exercise stress testing, to receive either increasing doses of escitalopram or placebo for 6 weeks. Endpoint mental and exercise stress testing were repeated at the end of 6 weeks for detection of MSIMI and ESIMI. Higher rate of patients taking escitalopram did not experience MSIMI vs. placebo (34.2% vs. 17.5%) and this rate was statistically significant (OR, 2.62 [95% CI, 1.06 to 6.44]; p=0.04). There was no statistically significant difference in ESIMI between the two groups (OR, 1.24[95% CI, 0.60 to 2.58]; p=0.56). Significantly higher rates of participants in the escitalopram group reported adverse effects vs. placebo (71.9% vs 44.4%, p=0.002).

By Elizabeth Park and Rif Rahman

More from this author: Trigger exposure in migraine patients results in migraine with aura only in a small subset of patients, Choosing a prenatal diagnostic test: Microarray analysis shown equal to karyotyping,STEMO unit delivery of tpa reduces call to needle time in acute stroke patients,High-dose multivitamin supplements do not decrease disease progression or death in HIV patients receiving HAART ,Pediatric patients not receiving quality palliative care despite agreement between parents and caregivers on valued elements of care ,Combined BRAF and MEK inhibition in metastatic melanoma significantly improves progression free survival

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: AntidepressantcardiologyClinical trialsdepressionEscitalopramhealthheart attacklexapromycardial ischemiapsychiatryREMITstress
Previous Post

Delayed tracheostomy in critically ill does not increase mortality

Next Post

Prone positioning decreases mortality in severe ARDS (PROSEVA Trial)

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Cardiology

Febuxostat may be effective in preventing contrast-induced acute kidney injury

March 27, 2023
Cardiac mortality paradoxically lower during times of national cardiology conferences
Cardiology

72- and 36-hour fever prevention post-cardiac arrest equivalent in preventing mortality

March 24, 2023
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Synergistic interaction between risk burden and genetics for atrial fibrillation development

March 21, 2023
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Weekly Rewinds

2 Minute Medicine Rewind March 20, 2023

March 20, 2023
Next Post
Prone positioning decreases mortality in severe ARDS (PROSEVA Trial)

Prone positioning decreases mortality in severe ARDS (PROSEVA Trial)

Immunotherapy shows efficacy for pediatric allergic asthma and rhinitis

Acellular Pertussis vaccine less effective than whole-cell vaccine

Early risk factor for progression of cystic fibrosis identified

Early risk factor for progression of cystic fibrosis identified

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Abnormal menstruation may be associated with worse cardiometabolic outcomes later in life
  • Past infection with pre-omicron variants of COVID-19 protects against re-infection
  • No difference in complete expulsion of intrauterine device between early and standard interval postpartum placement
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options